Abcam, ab256354, Anti-C5a antibody [EPR19699-24] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal C5 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR19699-24,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab256354 is the carrier-free version of
ab202039
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
C5a also known as complement component 5a is a 74-amino acid peptide with a molecular mass of approximately 11 kDa. It is expressed in the blood and is a fragment that forms when the complement system part of the body’s immune response activates. As a potent anaphylatoxin C5a plays a role in mediating inflammation and recruiting white blood cells to an infection site. It interacts with C5a receptors C5aR1 and C5aR2 located on various immune cells including neutrophils monocytes and macrophages.
Biological function summary
C5a functions as part of the complement cascade a complex series of events essential for opsonization cell lysis and inflammation. C5a binds to its receptors initiating cell responses such as chemotaxis increased vascular permeability and release of pro-inflammatory cytokines. These processes help in pathogen clearance making C5a a significant player in innate immunity. C5a exists as part of the larger complement system that includes proteins like C3 and C5 forming an important arm of the body's defense against pathogens.
Pathways
C5a integrates into the complement pathway and the coagulation cascade. It drives actions in the inflammatory response enhancing immune defense by promoting cytokine production and leukocyte migration. Important interactions occur with complement proteins such as C3 and C5b-9 key elements of the terminal complement complex. By influencing these pathways C5a directly contributes to both immune modulation and inflammatory processes.
C5a is linked to conditions such as sepsis and rheumatoid arthritis. In these diseases C5a contributes to excessive inflammation and tissue damage. C5a's interaction with C5aR1 and other receptors like CR1 involved in inflammatory regulation exemplifies its role in advancing disease states. Therapeutically targeting C5a and its receptors remains an active area of research aiming to develop treatments for conditions driven by dysregulated complement activation.